Articles with public access mandates - Spencer Phillips HeyLearn more
Not available anywhere: 13
Countering imprecision in precision medicine
SP Hey, AS Kesselheim
Science 353 (6298), 448-449, 2016
Mandates: Canadian Institutes of Health Research, Genome Canada
A Systematic Review Of The Food And Drug Administration’s ‘Exception From Informed Consent’ Pathway
WB Feldman, SP Hey, AS Kesselheim
Health Affairs 37 (10), 1605-1614, 2018
Mandates: Arnold Ventures LLC
A search filter to identify pragmatic trials in MEDLINE was highly specific but lacked sensitivity
M Taljaard, S McDonald, SG Nicholls, K Carroll, SP Hey, JM Grimshaw, ...
Journal of Clinical Epidemiology 124, 75-84, 2020
Mandates: National Health and Medical Research Council, Australia, Canadian Institutes …
Research ethics for emerging trial designs: does equipoise need to adapt?
SP Hey, C Weijer, M Taljaard, AS Kesselheim
Bmj 360, 2018
Mandates: Canadian Institutes of Health Research, Arnold Ventures LLC
Challenges and opportunities for biomarker validation
SP Hey, E D'Andrea, EH Jung, F Tessema, J Luo, B Gyawali, ...
The Journal of Law, Medicine & Ethics 47 (3), 357-361, 2019
Mandates: Arnold Ventures LLC
Ethics and epistemology of accurate prediction in clinical research
SP Hey
Journal of Medical Ethics 41 (7), 559-562, 2015
Mandates: Canadian Institutes of Health Research
Epistemology, ethics, and progress in precision medicine
SP Hey, B Barsanti-Innes
Perspectives in biology and medicine 59 (3), 293-310, 2016
Mandates: Canadian Institutes of Health Research, Genome Canada
Surrogate endpoints and drug regulation: what is needed to clarify the evidence
SP Hey, WB Feldman, EH Jung, E D'Andrea, AS Kesselheim
The Journal of Law, Medicine & Ethics 47 (3), 381-387, 2019
Mandates: Arnold Ventures LLC
Thinking clearly about the FIRST trial: addressing ethical challenges in cluster randomised trials of policy interventions involving health providers
AR Horn, C Weijer, SP Hey, J Brehaut, DA Fergusson, CE Goldstein, ...
Journal of medical ethics 44 (9), 593-598, 2018
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Why high drug pricing is a problem for research ethics
SP Hey
Journal of Bioethical Inquiry 17 (1), 29-35, 2020
Mandates: Arnold Ventures LLC
Heuristics and Explanation in Translational Medicine
SP Hey
Perspectives in Biology and Medicine 62 (4), 675-689, 2019
Mandates: Arnold Ventures LLC
Opioid use disorder treatments: an evidence map
A Sugarman, A Vittitow, A Cheng, M Malone, R McDonald, N Pace, ...
Drug and alcohol dependence 241, 109657, 2022
Mandates: US National Institutes of Health, Arnold Ventures LLC
Defining “True and Non-Misleading” for Pharmaceutical Promotion
SP Hey, AS Kesselheim
The Journal of Law, Medicine & Ethics 46 (2), 552-554, 2018
Mandates: Arnold Ventures LLC
Available somewhere: 35
Assessment of the clinical benefit of cancer drugs receiving accelerated approval
B Gyawali, SP Hey, AS Kesselheim
JAMA Internal Medicine 179 (7), 906-913, 2019
Mandates: Arnold Ventures LLC
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
A Haslam, SP Hey, J Gill, V Prasad
European Journal of Cancer 106, 196-211, 2019
Mandates: Arnold Ventures LLC
The questionable use of unequal allocation in confirmatory trials
SP Hey, J Kimmelman
Neurology 82 (1), 77-79, 2014
Mandates: Canadian Institutes of Health Research
Are outcome-adaptive allocation trials ethical?
SP Hey, J Kimmelman
Clinical Trials 12 (2), 102-106, 2015
Mandates: Canadian Institutes of Health Research, Genome Canada
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
B Gyawali, SP Hey, AS Kesselheim
EClinicalMedicine 21, 2020
Mandates: Arnold Ventures LLC
Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis
E D’Andrea, SP Hey, CL Ramirez, AS Kesselheim
JAMA network open 2 (4), e192224-e192224, 2019
Mandates: Arnold Ventures LLC
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib
B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ...
Journal of the National Cancer Institute 108 (1), djv292, 2016
Mandates: Canadian Institutes of Health Research
Publication and funding information is determined automatically by a computer program